Evidences of efficacy of allergen immunotherapy in atopic dermatitis: An updated review

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 4, 2012, Pages 427-433

  Compalati, Enrico ^a   Rogkakou, Anthi ^a   Passalacqua, Giovanni ^a   Canonica, Giorgio W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

allergen immunotherapy; atopic dermatitis; atopic eczema; efficacy; evidence

Indexed keywords

ALLERGEN; PLACEBO;

ARTICLE; ATOPIC DERMATITIS; DESENSITIZATION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; IMMUNOTHERAPY; PLACEBO EFFECT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT;

ALLERGENS; DERMATITIS, ATOPIC; ECZEMA; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84864279862     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328354e540     Document Type: Article

References (38)

1. Asher MI, Montefort S, Björksten B, et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-743. (Pubitemid 44279052)
2. Schram ME, Tedja AM, Spijker R, et al. Is there a rural/urban gradient in the prevalence of eczema A systematic review. Br J Dermatol 2010; 162:964-973.
3. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006; 118:3-21. (Pubitemid 43946484)
4. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008; 121:1337-1343.
5. Scharschmidt TC, Man MQ, Hatano Y, et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol 2009; 124:496-506.
6. Weidinger S, Illig T, Barecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118:214-219. (Pubitemid 43949588)
7. Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol 2008; 121:872-877.
8. Chase EP, Armstrong AW. Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments. Semin Cutan Med Surg 2012; 31:17-24.
9. Tarr A, Iheanacho I. Should we use bath emollients for atopic eczema BMJ 2009; 339:b4273.
10. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010; 21:144-156.
11. Frankel HC, Qureshi AA. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 2012; 13:113-123.
12. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118:226-232. (Pubitemid 43946465)
13. Bath-Hextall FJ, Jenkinson C, Humphreys R, et al. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev 2012; 2:CD005205.
14. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for the treatment of eczema: a systematic review. Clin Exp Allergy 2009; 39:1117-1127.
15. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010; 105:99-106.
16. Weidinger S, OSullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121:1203-1209.
17. Marenholz I, Nickel R, Ruschendorf F, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 2006; 118:866-871. (Pubitemid 44498766)
18. Park JH, Choi YL, Namkung JH, et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol 2006; 155:778-783.
19. Fuiano N, Incorvaia C. Dissecting the causes of atopic dermatitis in children: less foods, more mites. Allergol Int 2012. [Epub ahead of print]
20. Hostetler SG, Kaffenberger B, Hostetler T, Zirwas MJ. The role of airborne proteins in atopic dermatitis. J Clin Aesthet Dermatol 2010; 3:22-31.
21. Bohle B. The impact of pollen-related food allergens on pollen allergy. Allergy 2007; 62:3-10. (Pubitemid 44902728)
22. Frew AJ. Hundred years of allergen immunotherapy. Clin Exp Allergy 2011; 41:1221-1225.
23. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl):S1-S55.
24. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007; 7:542-546. (Pubitemid 350076451)
25. Rosenwasser LJ. Critical documents on cows milk allergy and anaphylaxis: two recent wao position papers. World Allergy Organ J 2011; 4:76.
26. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: world allergy organization position paper. World Allergy Organ J 2009; 2:233-281.
27. Köberlein J, Vent, Mösges R. On the sustainability of guideline implementation. World Allergy Organ J 2010; 3:258-261.
28. Bussmann C, Böckenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118:1292-1298. (Pubitemid 44854122)
29. Shams K, Grindlay DJC, Williams HC. Whats new in atopic eczema An analysis of, systematic reviews published in 2009-2010. Clin Exp Dermatol 2011; 36:573-577.
30. Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep 2011; 11:277-283.
31. Pajno GB, Finegold I. SIT beyond respiratory diseases. Ann Allergy Asthma Immunol 2011; 107:395-400.
32. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2 [updated September 2009]. Cochrane Collaboration; 2009. www.cochrane-handbook.org.
33. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatis-results of a double blind randomized controlled study. Pl Merk lek, 2006; 21:126, 558-565. (Pubitemid 46129193)
34. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mitesensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120:164-170. (Pubitemid 46990495)
35. Czarnecka-Operacz M, Silny W. Specific immunotherapy in atopic dermatitis: four-year treatment in different age and airborne allergy type subgroups. Acta Dermatovenerol Croat 2006; 14:230-240. (Pubitemid 46154746)
36. Shi H, Wang X, Ren H, Zhuang Y. Effect analysis of the dust mite allergenspecific, immunotherapy of chronic eczema. Chin J Derm Venereol 2010; 24:424-426.
37. Zheng J. Clinical study on sublingual immunotherapy for allergens of children with atopic, dermatitis. Hebei Med 2011; 17:149-150.
38. Silny W, Czarnecka-Operacz M, Golebka E, Silny P. W-AZS a new scoring index for patients with atopic dermatitis. Przegl Dermatol 1999; 86:215-222.